04 / 74 · 1:04 · Original AXON film
BPC-157
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
BPC-157 | Research history
BPC-157 is often introduced through its gastric-protection research history. Much of the attention now comes from studies of injured tissue. [1] [2]
CELLS + RATS
Researchers have investigated tendon-cell movement, survival and tissue repair in laboratory and rat experiments. These findings help generate hypotheses about how a treatment might work. [1] [2]
Translation to patients remains uncertain
They do not tell us how reliably an injury will heal in a person, what long-term harms could occur, or whether an online product matches the material studied. [3]
Experimental | Avoid healing guarantees
FDA’s 2026 assessment identified major evidence and safety gaps. A promising animal result is a reason to investigate carefully, not a basis for calling BPC-157 a proven repair therapy. [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration →Primary rat tendon explant and tendon-cell study
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth →Primary rat injury and cell study
- FDA Pharmacy Compounding Advisory Committee briefing: BPC-157-related bulk drug substances →US regulator technical assessment; July 2026 advisory process, not marketing approval
